Cynosure Group LLC Makes New Investment in Moderna, Inc. $MRNA

Cynosure Group LLC purchased a new position in shares of Moderna, Inc. (NASDAQ:MRNA) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 16,836 shares of the company’s stock, valued at approximately $496,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of Moderna by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 41,584,782 shares of the company’s stock valued at $1,226,335,000 after purchasing an additional 399,487 shares during the period. Capital World Investors bought a new stake in shares of Moderna in the 4th quarter valued at about $378,299,000. Invesco Ltd. raised its holdings in shares of Moderna by 15.7% in the 3rd quarter. Invesco Ltd. now owns 8,216,163 shares of the company’s stock valued at $212,223,000 after purchasing an additional 1,115,131 shares during the period. Theleme Partners LLP raised its holdings in shares of Moderna by 2.5% in the 3rd quarter. Theleme Partners LLP now owns 8,068,810 shares of the company’s stock valued at $208,417,000 after purchasing an additional 200,000 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Moderna by 7.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 4,621,558 shares of the company’s stock valued at $136,290,000 after purchasing an additional 309,126 shares during the period. 75.33% of the stock is owned by institutional investors.

Moderna News Summary

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: FDA staff said Moderna’s flu vaccine data may support effectiveness in adults 65 and older, a constructive sign ahead of a key advisory meeting that could improve the odds of approval. US FDA staff says data may support effectiveness of Moderna’s flu vaccine in older adults
• Positive Sentiment: Moderna announced organizational changes, including a new chief commercial officer and an expanded role for President Stephen Hoge, signaling the company is preparing more aggressively for potential product launches in 2027 and 2028. Moderna Announces Organizational Changes to Prepare for Multiple Product Launches in 2027 and 2028
• Positive Sentiment: Market commentary noted renewed investor attention on Moderna after the FDA review and leadership updates, reinforcing optimism around the company’s late-stage vaccine pipeline. Why Moderna Is Capturing Market Attention Again?
• Neutral Sentiment: Several reports framed the move as a reaction to the FDA’s balanced review and broader speculation about a potential first mRNA flu shot, but these developments are still dependent on the upcoming advisory process. Why is Moderna (MRNA) stock soaring today?
• Negative Sentiment: FDA staff also scrutinized the evidence supporting the flu vaccine, highlighting that approval is not guaranteed and leaving some regulatory risk in place. FDA staff scrutinizes evidence supporting Moderna’s flu vaccine

Insider Buying and Selling at Moderna

In other Moderna news, President Stephen Hoge sold 53,336 shares of the stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $48.40, for a total transaction of $2,581,462.40. Following the transaction, the president owned 1,477,997 shares in the company, valued at $71,535,054.80. This represents a 3.48% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Abbas Hussain sold 5,682 shares of the stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $46.63, for a total transaction of $264,951.66. Following the transaction, the director owned 12,066 shares in the company, valued at approximately $562,637.58. The trade was a 32.01% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 71,752 shares of company stock worth $3,453,843. 10.80% of the stock is currently owned by company insiders.

Analyst Ratings Changes

MRNA has been the topic of a number of research analyst reports. Piper Sandler upped their target price on shares of Moderna from $63.00 to $69.00 and gave the company an “overweight” rating in a report on Monday, February 23rd. Barclays upped their target price on shares of Moderna from $25.00 to $48.00 and gave the company an “equal weight” rating in a report on Thursday, April 2nd. Bank of America upped their target price on shares of Moderna from $32.00 to $34.00 and gave the company an “underperform” rating in a report on Monday, June 8th. UBS Group reaffirmed a “neutral” rating on shares of Moderna in a report on Tuesday, May 26th. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $45.00 target price on shares of Moderna in a report on Tuesday, February 17th. Two analysts have rated the stock with a Buy rating, eleven have given a Hold rating and five have issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Reduce” and an average target price of $36.60.

Moderna Stock Up 6.3%

Shares of MRNA opened at $55.40 on Wednesday. Moderna, Inc. has a 52 week low of $22.28 and a 52 week high of $59.55. The firm has a market cap of $21.98 billion, a P/E ratio of -6.80 and a beta of 1.05. The firm’s 50-day simple moving average is $49.79 and its 200 day simple moving average is $44.57. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.35 and a current ratio of 2.41.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Friday, May 1st. The company reported ($3.40) EPS for the quarter, missing analysts’ consensus estimates of ($3.02) by ($0.38). Moderna had a negative net margin of 143.55% and a negative return on equity of 26.64%. The company had revenue of $389.00 million during the quarter, compared to analyst estimates of $236.37 million. During the same quarter last year, the company posted ($2.52) EPS. The firm’s quarterly revenue was up 260.2% on a year-over-year basis. On average, analysts forecast that Moderna, Inc. will post -6.51 earnings per share for the current year.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.